Moderna and Merck announced on August 19-21, 2026, that a personalized mRNA cancer vaccine combined with the drug Keytruda significantly reduced the risk of melanoma recurrence and spread in high-risk patients during late-stage trials, marking a major breakthrough in therapeutic cancer vaccines.
No BS check run yet — press ⚖ to extract this story's claims and verify them against independent sources.
Result in high-risk patients validates decades of research into mRNA-based therapeutic cancer vaccines.
this outlet adds: experimental, succeeded, preventing, coming, back, spreading, study, results
this outlet adds: little, baffled, sometimes, working, books, writing, sports, while
The companies say the vaccine prevented the return and spread of the cancer in high-risk melanoma patients.
this outlet adds: nytimes, 2026, experimental
this outlet adds: nytimes, 2026, experimental
An experimental personalized mRNA-based cancer vaccine from Merck and Moderna was successful at preventing melanoma from returning or spreading in a late-stage trial of high risk patients, the companies announced Wednesday. The positive results mean a potentially life-extending treatment is one step closer to being available on the market. They also herald a significant and...
this outlet adds: thehill, policy, healt
[The Wall Street Journal-Gifted article]: Moderna Shares Double on Success of mRNA Cancer Vaccine Result from Merck-Moderna partnership validates years of research into mRNA-based therapeutic cancer vaccines. By Xavier Martinez and Alex Janin, August 19, 2026. https://www. wsj.com/health/pharma/moderna- merck-vaccine-succeeds-in-preventing-melanoma-from-returning-540e9e18?st=heo4GH # melanoma # ca
www.westernslopenow.com/news/nationa... The study also met a secondary goal of preventing cancer from spreading to different parts of the body.
Moderna and Merck said the personalised vaccine reduced the risk of recurrence and spread of melanoma in a late-stage trial, a major success in a new field of cancer treatment.
Explore this gift article from The New York Times. You can read it for free without a subscription. www.nytimes.com/2026/08/19/s... Moderna and Merck say the experimental vaccine prevented the return and spread of the cancer in high-risk melanoma patients.
CBS News medical correspondent Dr. Céline Gounder, who has had melanoma herself, said Moderna's experimental trial is "a big win for mRNA vaccines against cancer."
reason.com/2026/08/19/b... A breakthrough mRNA anti-cancer vaccine that successfully treats late stage melanoma skin cancer could be approved by next year.
Drug manufacturers Moderna and Merck say a personalized mRNA cancer vaccine plus a drug called Keytruda reduced the return and spread of melanoma in high-risk patients. Dr. Jon LaPook and trial researcher Dr. Janice Mehnert have more information.
How should we think about using new cancer vaccines in our healthcare systems? Where do YOU stand? Join the debate: Moderna and Merck say the experimental vaccine prevented the return and spread of the cancer in high-risk melanoma patients
IGC Senior Clinical Research Fellow Mark Stares ran part of this international clinical trial of an experimental mRNA vaccine developed by pharmaceutical companies Moderna and @merckgroup.bsky.social to help prevent the return and spread of cancer in high-risk melanoma patients 👉 edin.ac/4gnggHI An experimental mRNA vaccine developed by pharmaceutical companies Moderna and Merck helped prevent th